SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy
- PMID: 35164561
- PMCID: PMC8844933
- DOI: 10.1128/mbio.03227-21
SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) harbor mutations in the spike (S) glycoprotein that confer more efficient transmission and dampen the efficacy of COVID-19 vaccines and antibody therapies. S mediates virus entry and is the primary target for antibody responses, with structural studies of soluble S variants revealing an increased propensity toward conformations accessible to the human angiotensin-converting enzyme 2 (hACE2) receptor. However, real-time observations of conformational dynamics that govern the structural equilibriums of the S variants have been lacking. Here, we report single-molecule Förster resonance energy transfer (smFRET) studies of critical mutations observed in VOCs, including D614G and E484K, in the context of virus particles. Investigated variants predominately occupied more open hACE2-accessible conformations, agreeing with previous structures of soluble trimers. Additionally, these S variants exhibited slower transitions in hACE2-accessible/bound states. Our finding of increased S kinetic stability in the open conformation provides a new perspective on SARS-CoV-2 adaptation to the human population. IMPORTANCE SARS-CoV-2 surface S glycoprotein-the target of antibodies and vaccines-is responsible for binding to the cellular receptor hACE2. The interactions between S and hACE2 trigger structural rearrangements of S from closed to open conformations prerequisite for virus entry. Under the selection pressure imposed by adaptation to the human host and increasing vaccinations and convalescent patients, SARS-CoV-2 is evolving and has adopted numerous mutations on S variants. These promote virus spreading and immune evasion, partially by increasing the propensity of S to adopt receptor-binding competent open conformations. Here, we determined a time dimension, using smFRET to delineate the temporal prevalence of distinct structures of S in the context of virus particles. We present the first experimental evidence of decelerated transition dynamics from the open state, revealing increased stability of S open conformations to be part of the SARS-CoV-2 adaption strategies.
Keywords: SARS-CoV-2 variants; conformational dynamics; single-molecule FRET; spike glycoprotein; structure.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants.Viruses. 2022 Jun 9;14(6):1255. doi: 10.3390/v14061255. Viruses. 2022. PMID: 35746726 Free PMC article. Review.
-
Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles.Cell Host Microbe. 2020 Dec 9;28(6):880-891.e8. doi: 10.1016/j.chom.2020.11.001. Epub 2020 Nov 13. Cell Host Microbe. 2020. PMID: 33242391 Free PMC article.
-
A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant.J Virol. 2022 Jul 13;96(13):e0068522. doi: 10.1128/jvi.00685-22. Epub 2022 Jun 8. J Virol. 2022. PMID: 35674432 Free PMC article.
-
Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach.mBio. 2021 Oct 26;12(5):e0268721. doi: 10.1128/mBio.02687-21. Epub 2021 Oct 26. mBio. 2021. PMID: 34700382 Free PMC article.
-
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants.Cell Mol Life Sci. 2021 Dec;78(24):7967-7989. doi: 10.1007/s00018-021-04008-0. Epub 2021 Nov 3. Cell Mol Life Sci. 2021. PMID: 34731254 Free PMC article. Review.
Cited by
-
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.mBio. 2024 Aug 14;15(8):e0090724. doi: 10.1128/mbio.00907-24. Epub 2024 Jul 2. mBio. 2024. PMID: 38953636 Free PMC article.
-
Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid.Sci Adv. 2024 Jul 19;10(29):eadk4920. doi: 10.1126/sciadv.adk4920. Epub 2024 Jul 17. Sci Adv. 2024. PMID: 39018397 Free PMC article.
-
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies.Nat Rev Microbiol. 2023 Feb;21(2):112-124. doi: 10.1038/s41579-022-00809-7. Epub 2022 Oct 28. Nat Rev Microbiol. 2023. PMID: 36307535 Free PMC article. Review.
-
Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants.Viruses. 2022 Jun 9;14(6):1255. doi: 10.3390/v14061255. Viruses. 2022. PMID: 35746726 Free PMC article. Review.
-
Evolution of transient RNA structure-RNA polymerase interactions in respiratory RNA virus genomes.Virus Evol. 2023 Aug 26;9(2):vead056. doi: 10.1093/ve/vead056. eCollection 2023. Virus Evol. 2023. PMID: 37692892 Free PMC article.
References
-
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Kehtan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group . 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416. doi:10.1056/NEJMoa2035389. - DOI - PMC - PubMed
-
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group . 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615. doi:10.1056/NEJMoa2034577. - DOI - PMC - PubMed
-
- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, Oxford COVID Vaccine Trial Group, et al. . 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111. doi:10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
-
- Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. 2021. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 384:1824–1835. doi:10.1056/NEJMoa2034201. - DOI - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
